There has been a general consensus in fact, that the HER-2 oncogene, when overexpressed, is the dominant driver of breast cancer biology, regardless of HR status [6], and current guidelines support the use of anti-HER-2 agents combined with chemotherapy in all the disease settings. Here, ERBB2 is linked to breast cancer.